AI Ambition in the Life Sciences Is Fast Outpacing Data Foundations

AI Has Moved from Speculative Asset to Strategic Imperative

AI disruption isn’t happening at the fringes of the enterprise. According to the IBV, 69% of life sciences CEOs say AI is changing aspects of their business that they consider core. At the same time, 90% of life sciences CDOs prioritize investments that accelerate AI capabilities and initiatives. That shift is visible across the value chain.

In R&D, AI and machine learning are accelerating early-stage discovery by analyzing large datasets, optimizing candidate selection, and identifying novel molecules. In clinical development, AI and analytics are helping improve trial design, site selection, patient matching, recruitment, and retention. In regulatory operations, generative and agentic AI are increasingly being applied to document creation, submission preparation, regulatory tracking, and workflow automation.

The opportunity extends well beyond the lab. AI can also help life sciences organizations optimize manufacturing and supply chains, improve diagnostics, streamline operations, and personalize patient experiences.

Naturally, the common denominator across all these applications is data. Despite their best efforts, however, that is where most of the industry still has a lot of work to do.

The Data Gap Is Becoming an AI Gap

The life sciences industry generates enormous volumes of clinical, genomic, research, manufacturing, commercial, and real-world data. The challenge enterprises in the space still face is making that data accessible, interoperable, governed, and useful across organizational boundaries.

The IBV findings illustrate the problem starkly: while 82% of CDOs see proprietary data as strategically important for differentiation, only 25% of COOs say their organizations have fully developed the enterprise-wide data architecture and integration required to support it.

That gap matters because AI does not create value simply by being connected to more data. It creates value when it can reason over trusted, contextualized, interoperable data. Sure, a model can generate an answer to a given query in a matter seconds. What that doesn’t guarantee is that said answer is a useful one.

If clinical data sits in one system, research data in another, manufacturing data still somewhere else, and critical business definitions exist only within individual functions, an AI application has to reconstruct context before it can produce an answer that the business can trust.

The result is familiar: more integration work, more reconciliation, more bespoke pipelines, and more time spent preparing data instead of using it.

Proprietary Data Is the Differentiator

Despite the overwhelming ramifications of the industry’s data maturity problem, the finding that 73% of life sciences CEOs see proprietary data as key to unlocking generative AI value offers another clue into what factors will separate the haves and have-nots in the year ahead.

Foundation models are increasingly accessible. The differentiating asset is becoming the proprietary data and institutional knowledge an organization can bring to those models.

For life sciences companies, that includes information like:

• Clinical trial and patient data.
• Genomic and molecular datasets.
• Research and laboratory data.
• Manufacturing and quality data.
• Supply chain and demand data.
• Regulatory and submission data
• Commercial and market data

Individually, each dataset can be valuable. Connected and governed, they can become a foundation for entirely new forms of analysis and decision support. That is the opportunity behind an AI-ready data platform: not simply consolidating data, but making the relationships between data discoverable and usable by both people and machines.

From Analytics to Agentic AI

The next evolution makes this even more important. Traditional analytics asks people to find the right data, build the right query, and interpret the result. AI-powered analytics can make that interaction more natural. Agentic AI takes another step, allowing systems to reason across information, execute multi-step workflows, and assist with decisions.

In life sciences, the potential applications are significant. An agent could help a clinical operations team identify trial sites with recruitment challenges and surface the factors contributing to underperformance. A research agent could bring together experimental results, internal knowledge, and external literature to help scientists investigate a hypothesis. A regulatory agent could assemble information from multiple systems to support submission preparation or track regulatory changes.

IBV identifies similar opportunities across discovery, clinical trials, patient care, laboratory operations, and regulatory workflows. But agentic AI also raises the stakes. The more autonomy an AI system has, the more important it becomes that the data it can access is governed, contextualized, traceable, and secure.

Trust Is Part of the Data Architecture

In life sciences, AI cannot be separated from questions of safety, compliance, explainability, and trust. 70% of life sciences CEOs say customer trust will have a greater impact on organizational success than any specific product or service. And 85% say transparency around the adoption of new technologies is critical to fostering trust.

That makes governance more than an AI policy exercise. It has to be embedded into the underlying data and technology architecture. The IBV recommends enterprise-wide principles for fairness, safety, transparency, and human oversight, along with cross-functional governance spanning quality, regulatory, IT, legal, and clinical stakeholders. It also emphasizes data lineage, privacy, bias management, continuous monitoring, and model drift detection.

For organizations building AI at scale, that means governance cannot be something added after the model is deployed. It has to travel with the data.

The State of Life Sciences Tells a Data Story

The industry is at an interesting inflection point. The appetite for AI is clear. 90% of life sciences CDOs are prioritizing investments that accelerate AI capabilities. 69% of CEOs say AI is changing core aspects of their businesses. And 69% also say competitive advantage depends on who has the most advanced generative AI.

But ambition alone does not create an AI advantage. The organizations best positioned to capitalize on these technologies will be the ones that treat data as strategic infrastructure: connected across functions, governed by design, enriched with business context, and accessible to the AI systems being built on top of it.

The goal, then, is not to build more AI pilots. It is to create a foundation where the next AI use case is faster, safer, and less expensive to build than the last one. That is the shift life sciences leaders should be planning for now.